[HTML][HTML] Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular Cancer, 2023 - Springer
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis …
L Zhang, L Wang, J Wang, J Chen, Z Meng… - Molecular …, 2023 - search.proquest.com
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular …, 2023 - go.gale.com
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
[HTML][HTML] Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular …, 2023 - ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis …
L Zhang, L Wang, J Wang, J Chen… - Molecular …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis …
L Zhang, L Wang, J Wang, J Chen, Z Meng… - Molecular …, 2023 - search.ebscohost.com
Background: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
[HTML][HTML] Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final …
L Zhang, L Wang, J Wang, J Chen… - Molecular …, 2023 - molecular-cancer.biomedcentral …
Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutation and concurrent mutations have a poor prognosis. This study aimed to examine …
mutation and concurrent mutations have a poor prognosis. This study aimed to examine …
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular …, 2023 - europepmc.org
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …